We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Brandon Capital Partners

Sofinnova Partners

Myricx Bio

FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners.

The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. 

Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. 

Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead.

Read the full release HERE https://lnkd.in/eSu9mP3c

#venturecapital #financing #drugdevelopment #UKbiotech

It was a pleasure meeting BiotechTV new European correspondent Amy Brown and explaining our excitement around the prospects for our #NMTi-ADCs. Great to be financed to take two programs into the clinic and further develop our NMTi payload platform.

🎉 #BIAmember Brandon Capital today announced the launch of their sixth fund with a $270 million initial close to drive #LifeScience innovation ➡️ https://ow.ly/u0QS50S89Kn

The new #Fund will support the growth of 🌏 #Australian and #NewZealand #LifeSciences startups, invest in scale-ups, and expand Brandon Capital’s international presence, particularly in the 📍 #UK, #Europe, and the #USA 🚀

More information in the link above 👆

Our CSO, Francesca Zammarchi, is speaking about our novel NMTi payload platform and pre-clinical efficacy studies for our lead ADCs at the ADC Payload Summit, Boston, MA on May 22nd at 12.30pm. 
#drugdiscovery #oncology #cancer  #antibodydrugconjugates

Overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want, according to a new report from J.P. Morgan.

Looking forward to seeing investors, partners and industry colleagues next week in San Francisco at #JPM24. Lots of positive progress and potential in the #ADC space, so exciting times ahead.

ADC Therapeutics is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) for the treatment of cancer.

ADC Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment.

Mersana Therapeutics

Seattle Genetics is a biotechnology company specializing in the development and commercialization of antibody-based therapies for cancer treatment, including antibody-drug conjugates (ADCs).

Seattle Genetics

Myricx Bio is a UK biotech company focused on the discovery and development of a novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Jul 9, 2024 7:55 AM	8427adf3
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 9, 2024 9:29 AM	ff444aa8
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Jul 9, 2024 7:55 AM	9db91201
news basic	general	Jul 9, 2024 7:55 AM	575db0c4
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:MYRICXBIO

Myricx Bio